Last reviewed · How we verify
Temozolomide, Cisplatinum
At a glance
| Generic name | Temozolomide, Cisplatinum |
|---|---|
| Sponsor | Gustave Roussy, Cancer Campus, Grand Paris |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas (PHASE1)
- Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer (PHASE2)
- A Phase II Trial of LM103 in Advanced Melanoma (PHASE2)
- Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation (EARLY_PHASE1)
- Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery (PHASE2)
- A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN). (PHASE2, PHASE3)
- Embryonal Tumor With Multilayered Rosettes (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Temozolomide, Cisplatinum CI brief — competitive landscape report
- Temozolomide, Cisplatinum updates RSS · CI watch RSS
- Gustave Roussy, Cancer Campus, Grand Paris portfolio CI